176 related articles for article (PubMed ID: 32364525)
21. CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.
Zhu Y; Wen J; Huang G; Mittlesteadt J; Wen X; Lu X
Prostate; 2021 Jan; 81(1):81-88. PubMed ID: 33022763
[TBL] [Abstract][Full Text] [Related]
22. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.
Geng C; He B; Xu L; Barbieri CE; Eedunuri VK; Chew SA; Zimmermann M; Bond R; Shou J; Li C; Blattner M; Lonard DM; Demichelis F; Coarfa C; Rubin MA; Zhou P; O'Malley BW; Mitsiades N
Proc Natl Acad Sci U S A; 2013 Apr; 110(17):6997-7002. PubMed ID: 23559371
[TBL] [Abstract][Full Text] [Related]
23. SPOP mutations promote p62/SQSTM1-dependent autophagy and Nrf2 activation in prostate cancer.
Shi Q; Jin X; Zhang P; Li Q; Lv Z; Ding Y; He H; Wang Y; He Y; Zhao X; Zhao SM; Li Y; Gao K; Wang C
Cell Death Differ; 2022 Jun; 29(6):1228-1239. PubMed ID: 34987184
[TBL] [Abstract][Full Text] [Related]
24. The TGF-β signalling negative regulator PICK1 represses prostate cancer metastasis to bone.
Dai Y; Ren D; Yang Q; Cui Y; Guo W; Lai Y; Du H; Lin C; Li J; Song L; Peng X
Br J Cancer; 2017 Aug; 117(5):685-694. PubMed ID: 28697177
[TBL] [Abstract][Full Text] [Related]
25. The emerging role of speckle-type POZ protein (SPOP) in cancer development.
Mani RS
Drug Discov Today; 2014 Sep; 19(9):1498-502. PubMed ID: 25058385
[TBL] [Abstract][Full Text] [Related]
26. SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression.
Ma J; Chang K; Peng J; Shi Q; Gan H; Gao K; Feng K; Xu F; Zhang H; Dai B; Zhu Y; Shi G; Shen Y; Zhu Y; Qin X; Li Y; Zhang P; Ye D; Wang C
J Exp Clin Cancer Res; 2018 Jul; 37(1):145. PubMed ID: 29996942
[TBL] [Abstract][Full Text] [Related]
27. Mutational and expressional analyses of SPOP, a candidate tumor suppressor gene, in prostate, gastric and colorectal cancers.
Kim MS; Je EM; Oh JE; Yoo NJ; Lee SH
APMIS; 2013 Jul; 121(7):626-33. PubMed ID: 23216165
[TBL] [Abstract][Full Text] [Related]
28. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.
Geng C; Rajapakshe K; Shah SS; Shou J; Eedunuri VK; Foley C; Fiskus W; Rajendran M; Chew SA; Zimmermann M; Bond R; He B; Coarfa C; Mitsiades N
Cancer Res; 2014 Oct; 74(19):5631-43. PubMed ID: 25274033
[TBL] [Abstract][Full Text] [Related]
29. Transcriptional downregulation of miR-133b by REST promotes prostate cancer metastasis to bone via activating TGF-β signaling.
Huang S; Wa Q; Pan J; Peng X; Ren D; Li Q; Dai Y; Yang Q; Huang Y; Zhang X; Zhou W; Yuan D; Cao J; Li Y; He P; Tang Y
Cell Death Dis; 2018 Jul; 9(7):779. PubMed ID: 30006541
[TBL] [Abstract][Full Text] [Related]
30. Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.
Bernasocchi T; El Tekle G; Bolis M; Mutti A; Vallerga A; Brandt LP; Spriano F; Svinkina T; Zoma M; Ceserani V; Rinaldi A; Janouskova H; Bossi D; Cavalli M; Mosole S; Geiger R; Dong Z; Yang CG; Albino D; Rinaldi A; Schraml P; Linder S; Carbone GM; Alimonti A; Bertoni F; Moch H; Carr SA; Zwart W; Kruithof-de Julio M; Rubin MA; Udeshi ND; Theurillat JP
Nat Commun; 2021 Feb; 12(1):734. PubMed ID: 33531470
[TBL] [Abstract][Full Text] [Related]
31. SPOP E3 Ubiquitin Ligase Adaptor Promotes Cellular Senescence by Degrading the SENP7 deSUMOylase.
Zhu H; Ren S; Bitler BG; Aird KM; Tu Z; Skordalakes E; Zhu Y; Yan J; Sun Y; Zhang R
Cell Rep; 2015 Nov; 13(6):1183-1193. PubMed ID: 26527005
[TBL] [Abstract][Full Text] [Related]
32. Potential Prognostic Role for SPOP, DAXX, RARRES1, and LAMP2 as an Autophagy Related Genes in Prostate Cancer.
Jamali L; Moradi A; Ganji M; Ayati M; Kazeminezhad B; Fazeli Attar Z; Ghaedi H; Ghaderian SMH; Fallah-Karkan M; Ranjbar A
Urol J; 2020 Mar; 17(2):156-163. PubMed ID: 30882175
[TBL] [Abstract][Full Text] [Related]
33. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer.
Theurillat JP; Udeshi ND; Errington WJ; Svinkina T; Baca SC; Pop M; Wild PJ; Blattner M; Groner AC; Rubin MA; Moch H; Prive GG; Carr SA; Garraway LA
Science; 2014 Oct; 346(6205):85-89. PubMed ID: 25278611
[TBL] [Abstract][Full Text] [Related]
34. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.
Janouskova H; El Tekle G; Bellini E; Udeshi ND; Rinaldi A; Ulbricht A; Bernasocchi T; Civenni G; Losa M; Svinkina T; Bielski CM; Kryukov GV; Cascione L; Napoli S; Enchev RI; Mutch DG; Carney ME; Berchuck A; Winterhoff BJN; Broaddus RR; Schraml P; Moch H; Bertoni F; Catapano CV; Peter M; Carr SA; Garraway LA; Wild PJ; Theurillat JP
Nat Med; 2017 Sep; 23(9):1046-1054. PubMed ID: 28805821
[TBL] [Abstract][Full Text] [Related]
35. SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
Hernández-Llodrà S; Segalés L; Juanpere N; Marta Lorenzo T; Salido M; Nonell L; David López T; Rodríguez-Vida A; Bellmunt J; Fumadó L; Cecchini L; Lloreta-Trull J
Prostate; 2021 Dec; 81(16):1267-1277. PubMed ID: 34533858
[TBL] [Abstract][Full Text] [Related]
36. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants.
An J; Wang C; Deng Y; Yu L; Huang H
Cell Rep; 2014 Feb; 6(4):657-69. PubMed ID: 24508459
[TBL] [Abstract][Full Text] [Related]
37. SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
Hernández-Llodrà S; Segalés L; Safont A; Juanpere N; Lorenzo M; Fumadó L; Rodríguez-Vida A; Cecchini L; Bellmunt J; Lloreta-Trull J
Prostate; 2019 Jul; 79(10):1156-1165. PubMed ID: 31090082
[TBL] [Abstract][Full Text] [Related]
38. Transcriptional Repressor DAXX Promotes Prostate Cancer Tumorigenicity via Suppression of Autophagy.
Puto LA; Brognard J; Hunter T
J Biol Chem; 2015 Jun; 290(25):15406-15420. PubMed ID: 25903140
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
Dai X; Gan W; Li X; Wang S; Zhang W; Huang L; Liu S; Zhong Q; Guo J; Zhang J; Chen T; Shimizu K; Beca F; Blattner M; Vasudevan D; Buckley DL; Qi J; Buser L; Liu P; Inuzuka H; Beck AH; Wang L; Wild PJ; Garraway LA; Rubin MA; Barbieri CE; Wong KK; Muthuswamy SK; Huang J; Chen Y; Bradner JE; Wei W
Nat Med; 2017 Sep; 23(9):1063-1071. PubMed ID: 28805820
[TBL] [Abstract][Full Text] [Related]
40. Enhanced autophagy and NFE2L2/NRF2 pathway activation in SPOP mutation-driven prostate cancer.
Gao K; Shi Q; Liu Y; Wang C
Autophagy; 2022 Aug; 18(8):2013-2015. PubMed ID: 35438056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
